Welcome to LookChem.com Sign In|Join Free

CAS

  • or

81090-34-8

Post Buying Request

81090-34-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

81090-34-8 Usage

Description

4-Bromo-2-isopropylaniline is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceuticals and chemical compounds. It is characterized by the presence of a bromine atom at the 4-position and an isopropyl group at the 2-position on the aniline molecule, which contributes to its unique chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
4-Bromo-2-isopropylaniline is used as a key intermediate in the synthesis of oxalylarylaminobenzoic acids, which are known as inhibitors of protein tyrosine phosphatase 1B (PTP1B). PTP1B is an enzyme that plays a significant role in the regulation of various cellular processes, including cell growth, differentiation, and metabolism. Inhibition of PTP1B has been linked to the modulation of insulin signaling and glucose homeostasis, making it a potential target for the development of treatments for type 2 diabetes and obesity.
In addition to its role in the synthesis of PTP1B inhibitors, 4-bromo-2-isopropylaniline may also be utilized in the production of other pharmaceutical agents, given its versatile chemical structure and reactivity. Its applications in the pharmaceutical industry are primarily driven by the need for novel compounds with potential therapeutic benefits, as well as the development of more efficient and cost-effective synthetic routes for the production of existing drugs.
Overall, 4-bromo-2-isopropylaniline is a valuable intermediate in the chemical and pharmaceutical industries, with its primary use being in the synthesis of PTP1B inhibitors. Its unique structural features and reactivity make it an essential component in the development of new drugs and therapeutic agents, contributing to advancements in medicine and healthcare.

Check Digit Verification of cas no

The CAS Registry Mumber 81090-34-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,1,0,9 and 0 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 81090-34:
(7*8)+(6*1)+(5*0)+(4*9)+(3*0)+(2*3)+(1*4)=108
108 % 10 = 8
So 81090-34-8 is a valid CAS Registry Number.

81090-34-8Upstream product

81090-34-8Downstream Products

81090-34-8Relevant articles and documents

DIAGNOSIS, TREATMENT AND PREVENTION OF NEUROTENSIN RECEPTOR-RELATED CONDITIONS

-

Paragraph 0124; 0126, (2018/03/01)

The present invention describes a compound of formula (I) which can be used in the diagnosis, treatment or prevention of neurotensin receptor-related conditions such as tumors and hematological malignancies.

Efficient synthesis of heterocyclic neurotensin receptor ligands by microwave-assisted aminocarbonylation

Lang, Christopher,Gmeiner, Peter

, p. 2474 - 2480 (2013/09/23)

Marking the heterocyclic neurotensin receptor antagonist SR142948A as a lead compound, the development of an efficient and a practical synthetic route to heterocyclic aryl carboxamides is reported. Thus, a highly efficient and flexible access to these carboxamides was elaborated by taking advantage of microwave-assisted aminocarbonylation reaction mediated by Mo(CO)6, Herrmann's palladacycle, [(t-Bu)3PH]BF4, and DBU.

Donor-substituted distyrylpyrazines: Influence of steric congestion on UV-Vis absorption and fluorescence

Wink, Christoph,Detert, Heiner

supporting information, p. 144 - 150 (2013/03/13)

Di(p-aminostyryl)pyrazines with voluminous substituents on the nitrogen and in the adjacent positions were prepared via twofold aldol condensation. Absorption and emission spectra are influenced by increasing steric hindrance because the orbital overlap between nitrogen and π-system is modulated by voluminous groups. Strong solvatochromism of the fluorescence and huge Stokes shifts result from amplified donor-acceptor interaction in the excited state. Protonation occurs at the terminal amino groups first, followed by protonation of the central pyrazine. With increasing strength of acid, absorption and emission spectra are first shifted to the blue followed by a redshift. Copyright

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 81090-34-8